In an 81-year-old man with diffuse large B‑cell lymphoma receiving rituximab miniCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) who has had his left‑ventricular ejection fraction decrease from 50‑55% to 45‑50% after three cycles, should doxorubicin be continued or stopped, and what is the recommended cardio‑oncology management?

Doxorubicin Continuation Decision in This Patient

In this 81-year-old man with DLBCL whose LVEF has declined from 50-55% to 45-50% after 3 cycles of R-miniCHOP, doxorubicin should NOT be permanently discontinued, but rather a comprehensive cardio-oncology intervention should be implemented immediately while carefully weighing continuation versus alternative regimens. 1

Immediate Cardio-Oncology Management

The 2020 ESMO consensus guidelines provide explicit recommendations for this exact scenario 1:

Required Actions Now:

• Urgent cardiology consultation (preferably cardio-oncology specialist)

• Initiate cardioprotective therapy immediately:

  • ACE inhibitors or ARBs
  • Beta-blockers (especially carvedilol, which has shown cardioprotective effects in anthracycline-induced cardiomyopathy) 1
  • Consider statin if concurrent coronary disease present

• Obtain cardiac biomarkers:

  • BNP or NT-proBNP
  • Troponin I or T
  • Perform cardiac-focused physical examination after each subsequent dose 1

• Repeat LVEF assessment after alternate doses of anthracycline-based chemotherapy if continued 1

Decision Algorithm for Doxorubicin Continuation

Key Considerations:

This patient's LVEF decline (approximately 5-10% decrease to 45-50%) places him in a critical decision zone. The guidelines specifically address asymptomatic patients with LVEF decrease of ≥10% from baseline to 50%, OR a decrease to ≥40% but <50% 1.

Three Management Options:

1. Continue doxorubicin with intensive monitoring (if patient remains asymptomatic and benefits outweigh risks):

   • Only if cardioprotective therapy initiated
   • Consider dexrazoxane addition (cardioprotective agent for anthracycline therapy) 1
   • Consider switching to liposomal doxorubicin (reduced cardiotoxicity profile) 1, 2
   • Repeat LVEF after every subsequent cycle

2. Switch to non-anthracycline regimen (preferred given age and cardiac status):

   • R-GCVP (rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone): 61% response rate in cardiac comorbidity patients 3
   • Bendamustine-rituximab: Effective alternative with minimal cardiac toxicity 4
   • R-miniCHOP without doxorubicin (continue with other agents)

3. Temporary hold with reassessment:

   • Initiate cardioprotective therapy
   • Reassess LVEF in 3-6 weeks
   • Resume if LVEF improves to >50% 1

Critical Risk Factors in This Patient

Age 81 years is a significant independent risk factor for anthracycline cardiotoxicity 5. Additional concerning features:

• Baseline LVEF already borderline (50-55%)
• Elderly population has reduced cardiac reserve
• History of ischemic heart disease would further increase risk (HR 3.15) 6

There is NO safe dose of anthracycline - even doses as low as 100 mg/m² have been associated with reduced cardiac function 5. After 3 cycles of miniCHOP, cumulative doxorubicin exposure is approximately 150 mg/m² (assuming 25 mg/m² per cycle in mini-CHOP regimen).

Recommended Approach for This Specific Patient

Given the patient's advanced age (81 years), borderline baseline LVEF, and documented decline, I recommend:

1. Immediately initiate cardioprotective therapy (ACE-I/ARB + beta-blocker)
2. Strongly consider switching to non-anthracycline regimen rather than continuing doxorubicin:
   • R-GCVP or bendamustine-rituximab are proven alternatives 4, 3
   • This avoids cumulative anthracycline cardiotoxicity while maintaining lymphoma control
3. If oncology team insists on anthracycline continuation:
   • Switch to liposomal doxorubicin (significantly reduced cardiotoxicity) 1, 2
   • Add dexrazoxane 1
   • Obtain troponin and BNP before each cycle
   • Repeat echocardiogram after EVERY subsequent cycle
   • Permanent discontinuation if LVEF drops below 40% or patient develops symptoms

Common Pitfalls to Avoid

• Do NOT wait for symptomatic heart failure - mortality from chemotherapy-induced heart failure is worse than many cancers 1
• Do NOT assume LVEF recovery means safety - re-cardiotoxicity occurs in 29% of patients who initially recover 6
• Do NOT underestimate cumulative risk - cardiotoxicity can manifest up to 13 years post-treatment 5
• Do NOT ignore the patient's age - elderly patients have both increased cardiotoxicity risk AND reduced tolerance for cardiac dysfunction

The benefit-risk assessment must prioritize both cancer cure AND cardiovascular survival, as cardiac death from chemotherapy can negate any oncologic benefit. 1